Blood Platelets Market Segmentation:
Application
The platelet function disorder segment is assumed to dominate the blood platelets market with a revenue of 51% by the end of 2035. The growth of this market is majorly driven by the growing prevalence of cancer among the population. Chronic myelogenous leukemia and various myeloma cancers result in the development of acquired platelet dysfunction in some cancer patients. Therefore, cancer patients often have to receive platelet transfusions. In addition, chronic platelet dysfunction increases the need for platelet transfusions. The incidence of myeloma in the UK is projected to increase by 11% between 2014 and 2035, reported as by Cancer Research UK Statistics 2021. These figures indicate an increasing demand for platelet transfusions in the treatment of cancer patients. Therefore, platelets are often given to such patients to reduce the need for red blood cells, surgical blood loss, and complications such as reoperation due to bleeding.
End Users
The hospital segment is predicted to witness the largest share of 72% during the time period. The expansion of the segment can be attributed on the back of the accessibility of talented experts in the hospitals. The blood platelets market is expanding as a result of an increase in hospital admissions for patients with cancer, hemophilia, and other severe platelet disorders. Furthermore, higher accessibility of blood parts in hospitals brings about expanded use of blood platelets, bringing about expanded reception. Also, blood platelets are in high demand in hospitals as a result of an increase in the number of surgeries and severe injuries that necessitate blood transfusions. Additionally, promotive reimbursement policies have resulted in high demand for blood platelets in the hospital segment.
Our in-depth analysis of the global market includes the following segments:
|
Application |
|
|
Platelets |
|
|
End User |
|
